AR122725A1 - Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos - Google Patents
Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismosInfo
- Publication number
- AR122725A1 AR122725A1 ARP210101737A ARP210101737A AR122725A1 AR 122725 A1 AR122725 A1 AR 122725A1 AR P210101737 A ARP210101737 A AR P210101737A AR P210101737 A ARP210101737 A AR P210101737A AR 122725 A1 AR122725 A1 AR 122725A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- unsubstituted
- substituted
- cycloalkyl
- halogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 title 1
- 102100032783 Protein cereblon Human genes 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 150000001721 carbon Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 102000001307 androgen receptors Human genes 0.000 abstract 1
- 108010080146 androgen receptors Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- -1 piperidine dione compound Chemical class 0.000 abstract 1
- 150000005458 piperidinediones Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
En el presente documento se proporcionan compuestos de piperidina diona que tienen la siguiente estructura de fórmula (1) en donde R¹, R², R³, R⁴, L, V, X, a y m son como se definen en el presente documento, composiciones que comprenden una cantidad eficaz de un compuesto de piperidina diona y métodos para tratar o prevenir una enfermedad mediada por receptores de andrógenos. Reivindicación 1: Un compuesto de fórmula (1) o sales, tautómeros, isotopólogos o estereoisómeros farmacéuticamente aceptables de los mismos, en donde R¹ es alquilo C₁₋₃; a es 1 ó 2; R² y R³ se seleccionan cada uno independientemente de H y alquilo C₁₋₃, o R² y R³ y el carbono al que están unidos forman un cicloalquilo C₃₋₆ sustituido o no sustituido; m es 0 - 8; cada R⁴ es alquilo C₁₋₃ independientemente sustituido o no sustituido, o dos grupos R⁴, junto con el mismo átomo de carbono o átomos de carbono adyacentes a los que están unidos, forman un cicloalquilo C₃₋₆ sustituido o no sustituido, o dos grupos R⁴ junto con los átomos de carbono no adyacentes a los que están unidos forman un heterociclilo de 4 - 7 miembros sustituido o no sustituido; X es N o CRX; RX es hidrógeno, halógeno, -O(alquilo C₁₋₆) o -(alquilo C₁₋₉); L es -O(alquilo C₁₋₆)-, -(alquilo C₁₋₆)O-, -O(alquilo C₁₋₆)O- o -(alquilo C₁₋₉)- sustituido o no sustituido; V es un compuesto de fórmula (2) en donde B es N, CH o CRB; cada RB se selecciona independientemente entre halógeno y alquilo C₁₋₆ sustituido o no sustituido; RC es halógeno, CF₃ o SF₅; R⁵ y R⁶ son alquilo C₁₋₃, o R⁵ y R⁶, junto con el átomo de carbono al que están unidos, forman un cicloalquilo C₃₋₆ sustituido o no sustituido o un heterociclilo de 3 - 6 miembros; y b es 0 - 2
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063043612P | 2020-06-24 | 2020-06-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR122725A1 true AR122725A1 (es) | 2022-09-28 |
Family
ID=79032406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210101737A AR122725A1 (es) | 2020-06-24 | 2021-06-23 | Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos |
Country Status (8)
Country | Link |
---|---|
US (2) | US11739075B2 (es) |
EP (1) | EP4171568A1 (es) |
JP (1) | JP2023531709A (es) |
KR (1) | KR20230027213A (es) |
CN (1) | CN115955979A (es) |
AR (1) | AR122725A1 (es) |
TW (1) | TW202216681A (es) |
WO (1) | WO2021262812A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021262815A1 (en) | 2020-06-24 | 2021-12-30 | Celgene Corporation | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
IL299256A (en) | 2020-06-24 | 2023-02-01 | Celgene Corp | Cerebellum binding compounds, their compounds and methods of treatment with them |
CN117580575A (zh) * | 2021-06-17 | 2024-02-20 | 南京明德新药研发有限公司 | 戊二酰亚胺取代的异噁唑稠环化合物及其应用 |
CA3231175A1 (en) | 2021-09-01 | 2023-03-09 | Xizang Haisco Pharmaceutical Co., Ltd. | Compound for degradation of bcl-2 family proteins and medical application thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11352351B2 (en) * | 2015-01-20 | 2022-06-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
EP3455218A4 (en) * | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
SG11202106506WA (en) | 2018-12-19 | 2021-07-29 | Celgene Corp | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
AU2019403207A1 (en) | 2018-12-19 | 2021-07-15 | Celgene Corporation | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
WO2021262815A1 (en) | 2020-06-24 | 2021-12-30 | Celgene Corporation | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
IL299256A (en) | 2020-06-24 | 2023-02-01 | Celgene Corp | Cerebellum binding compounds, their compounds and methods of treatment with them |
-
2021
- 2021-06-23 JP JP2022579835A patent/JP2023531709A/ja active Pending
- 2021-06-23 WO PCT/US2021/038625 patent/WO2021262812A1/en unknown
- 2021-06-23 EP EP21830097.8A patent/EP4171568A1/en active Pending
- 2021-06-23 AR ARP210101737A patent/AR122725A1/es unknown
- 2021-06-23 CN CN202180044305.0A patent/CN115955979A/zh active Pending
- 2021-06-23 TW TW110122924A patent/TW202216681A/zh unknown
- 2021-06-23 US US17/356,305 patent/US11739075B2/en active Active
- 2021-06-23 KR KR1020237002102A patent/KR20230027213A/ko unknown
-
2023
- 2023-07-07 US US18/219,511 patent/US20230348431A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11739075B2 (en) | 2023-08-29 |
EP4171568A1 (en) | 2023-05-03 |
KR20230027213A (ko) | 2023-02-27 |
US20210403453A1 (en) | 2021-12-30 |
TW202216681A (zh) | 2022-05-01 |
JP2023531709A (ja) | 2023-07-25 |
CN115955979A (zh) | 2023-04-11 |
US20230348431A1 (en) | 2023-11-02 |
WO2021262812A1 (en) | 2021-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR122725A1 (es) | Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos | |
AR122723A1 (es) | Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos | |
AR117139A1 (es) | Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl) | |
PE20200758A1 (es) | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3 | |
PE20221336A1 (es) | Compuestos triciclicos sustituidos | |
AR089019A1 (es) | Derivados modificados de 4-fenil-piridina | |
AR071717A1 (es) | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. | |
AR103828A1 (es) | INHIBIDORES DEL FACTOR TRANSFORMADOR DEL CRECIMIENTO b | |
AR115296A1 (es) | Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer | |
AR079689A1 (es) | Derivados de imidazo[1,2a]piridina, composiciones farmaceuticas que los comprenden y uso de los mismos en trastornos mieloproliferativos, leucemia y enfermedades inmunologicas e inflamatorias. | |
AR092288A1 (es) | Ligandos del receptor ep1 | |
AR122726A1 (es) | Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos | |
AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
AR090955A1 (es) | Aminas biciclicas c-17 de triterpenoides con actividad inhibidora de la maduracion del vih | |
AR116114A1 (es) | Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak | |
AR110298A1 (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
AR078321A1 (es) | Derivados de 2,4'-bipiridina como inhibidores de cinasa (cdk9) | |
AR064831A1 (es) | Derivados de espiropiperidina-glicinamida | |
PE20161379A1 (es) | Nuevos compuestos macrociclicos | |
AR054231A1 (es) | Composiciones farmaceuticas | |
PE20081113A1 (es) | Inhibidores virales policiclicos | |
AR119376A1 (es) | Compuestos heterocíclicos | |
AR057377A1 (es) | Derivados de cicloheptapiridina como inhibidores de tirosina quinasa. composiciones farmaceuticas | |
AR088638A1 (es) | Lactamas sustituidas por piperidinilo como moduladores de gpr119 | |
AR122986A1 (es) | Derivados de piridazina como inhibidores de alk5 y/o alk4 |